Fluidigm Gets EUA Nod For Home Sample Collection Kit For Advanta COVID-19 Assay

The FDA has granted Emergency Use (EUA) approval for Fluidigm Corporation's FLDM AZOVA COVID-19 test collection kit for use with the company's Advanta Dx SARS-CoV-2 RT-PCR Assay on its Biomark HD platform.

  • The kit is authorized for at-home self-collection by prescription only for individuals suspected of COVID-19 infection.
  • Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in saliva specimens.
  • The assay is only for use under the FDA's Emergency Use Authorization.
  • Price Action: FLDM shares are up 2.5% at $4.71 in market trading hours on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!